Table 1. Baseline characteristics.
| Clinical characteristics | n=51 | |
|---|---|---|
| Age, years | 53.9±11.4 | |
| Female sex | 33.3 (17/51) | |
| Race | White | 82.4 (42/51) |
| Black | 13.7 (7/51) | |
| Other | 3.9 (2/51) | |
| Body mass index, kg/m2 | 29.8±6.1 | |
| Abdominal obesity | 52.9 (27/51) | |
| eGFR – ml/min/1.73 m2 | 86.1±17.6 | |
| eGFR <60 ml/min/1.73 m2 | 0 (0/51) | |
| Type 2 diabetes | 0 (0/51) | |
| Sleep apnoea | 7.8 (4/51) | |
| Screening blood pressure (before anti-HTN med washout) | ||
| Office BP, mmHg | 144.5/92.1±13.6/10.4 | |
| Baseline blood pressure (after anti-HTN med washout) | ||
| Office BP, mmHg | 153.9/99.1±12.7/7.8 | |
| Daytime ABP, mmHg | 150.8/93.2±7.4/4.9 | |
| 24-hour ABP, mmHg | 142.7/87.2±7.8/5.0 | |
| Antihypertensive medications | ||
|
Number of antihypertensive medications at screening |
1.2±0.7 | |
| Antihypertensive load index at screening | 0.5±0.4 | |
| Number of antihypertensive medications at screening | 0 | 15.7 (8/51) |
| 1 medication | 51.0 (26/51) | |
| 2 medications in combination | 33.3 (17/51) | |
| Types of medication at screening | ||
| Renin-angiotensin system blockers | 58.8 (30/51) | |
| Angiotensin-converting enzyme inhibitor | 37.3 (19/51) | |
| Angiotensin receptor blocker | 19.6 (10/51) | |
| Direct renin inhibitor | 2.0 (1/51) | |
| Calcium channel blocker | 23.5 (12/51) | |
| Thiazide-like diuretic | 25.5 (13/51) | |
| Alpha-1 receptor blocker | 3.9 (2/51) | |
| Beta blocker | 5.9 (3/51) | |
| Values are mean±SD or % (n/N). Abdominal obesity was defined as a waist circumference >102 cm for men and >88 cm for women. ABP: ambulatory blood pressure; BP: blood pressure; eGFR: estimated glomerular filtration rate; HTN: hypertension; M: months | ||